Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cholangiocarcinoma (approved 2022)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cholangiocarcinoma (Phase 3)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Leukemia, Myeloid (Phase 2)
Mutation (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Receptors, Fibroblast Growth Factor (Phase 3)
Sarcoma (Phase 3)
Stomach Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue